Exhibit 10.50

 

	
Confidential   Treatment Requested
   Under 17 C.F.R. §§ 200.80(b)(4) and 240.24b-2
    	

    


 

CHANGE ORDER

 

LETTER OF PAYMENT AUTHORIZATION

 

14 Nov 2012

 

Gary Hattersley, Ph.D.

Vice President, Biology

RADIUS HEALTH, INC.

5th Floor

300 Technology Square

Cambridge, MA 02139

United States

 

	
RE:
    	
 
    	
STUDY   #    20033374
    	
 
    	
BLOOD   SAMPLE COLLECTION FROM FEMALE NON-HUMAN PRIMATES FOLLOWING A SINGLE   SUBCUTANEOUS DOSE OR TRANSDERMAL PATCH DOSE OF BA058
    
	
 
    	
 
    	
FINAL   PROTOCOL AND PROTOCOL AMENDMENT 1
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
STUDY   START:
    	
09 OCT   2012
    	
 
    	
STUDY   END:
    	
25   OCT 2012
    


 

Dear Dr. Hattersley,

 

This communication is to serve as a Letter of Payment Authorization (LOPA) for the above referenced study, which will be performed at Charles River Laboratories Preclinical Services as set forth below. Charles River Laboratories Preclinical Services shall perform these services in accordance with the existing Service Agreement executed between Charles River Laboratories Preclinical Services and Radius Health, Inc.  Once fully executed, this LOPA shall be incorporated into and made part of the existing Service Agreement.

 

The payment schedule and price of this Final Protocol and Protocol Amendment Adjustment is as follows:

 

	
·   $ [*]
    	
Final   Protocol Adjustment on Study 
    
	
 
    	
 
    
	
·   $ [*]
    	
Protocol   Amendment 1 Adjustment on Study
    
	
 
    	
 
    
	
·   $ [*]
    	
Total   Cost 
    
	
 
    	
 
    
	
·   $ 11,856
    	
Total   Cost with [*]% discount — Due upon adjustment billing
    


 

Total study cost:  $82,344

 

Final Protocol adjustment due to:

·                  Increased number of blood sample collections and processing

 

Protocol Amendment 1 adjustment due to:

·                  An additional dose day was added to the study design

·                  Increased number of blood sample collections and processing

·                  Additional dose site observations added

 

In the event the study design is altered, or the study is postponed or cancelled, payments will be amended as follows:

 

The price impact (if any) of the protocol amendment/change order will be submitted in writing.  If study prices increase the difference will be invoiced and payable upon acceptance by the Sponsor.  If study prices decrease, the Sponsor will be credited for the difference.

 

Charles River, 6995 Longley Lane, Reno, NV 89511

 




[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

Form No. LC-08-F04 Revised 05-18-06

 











 

As acceptance of this agreement, please sign this Letter of Payment Authorization and return to me at the letterhead address or fax to me at 775-682-2100.  Should you have any questions, please call me at 775-682-2386.

 

 

	
/s/   Gary Hattersley
    	
 
    	
/s/   Danielle M. Florey
    
	
Authorized   Sponsor Representative 
    	
 
    	
Danielle   M. Florey
    
	
 
    	
 
    	
Client Manager, Client Services  
    
	
Gary   Hattersley, SVP Preclinical Development
    	
 
    	
14 Nov 2012
    
	
Print   (Name and Title)
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
November 15,   2012
    	
 
    	
 
    
	
Date
    	
 
    	
 
    


 




[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Charles River, 6995 Longley Lane, Reno, NV 89511

 

2